|
1
|
Ferrari S, Meazza C, Palmerini E,
Tamburini A, Fagioli F, Cozza R, Ferraresi V, Bisogno G, Mascarin
M, Cefalo G, et al: Nonmetastatic osteosarcoma of the extremity.
Neoadjuvant chemotherapy with methotrexate, cisplatin, doxorubicin
and ifosfamide An Italian Sarcoma Group study (ISG/OS-Oss). Tumori.
100:612–619. 2014.
|
|
2
|
Zalupski MM, Rankin C, Ryan JR, Lucas DR,
Muler J, Lanier KS, Budd GT, Biermann JS, Meyers FJ and Antman K:
Adjuvant therapy of osteosarcoma - A phase II trial: Southwest
Oncology Group study 9139. Cancer. 100:818–825. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nagarajan R, Clohisy DR, Neglia JP, Yasui
Y, Mitby PA, Sklar C, Finklestein JZ, Greenberg M, Reaman GH,
Zeltzer L, et al: Function and quality-of-life of survivors of
pelvic and lower extremity osteosarcoma and Ewing's sarcoma: The
Childhood Cancer Survivor Study. Br J Cancer. 91:1858–1865. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Berg J, Gebhardt MC and Rand WM: Effect of
timing of postoperative chemotherapy on survival of dogs with
osteosarcoma. Cancer. 79:1343–1350. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Grignani G, Palmerini E, Ferraresi V,
D'Ambrosio L, Bertulli R, Asaftei SD, Tamburini A, Pignochino Y,
Sangiolo D, Marchesi E, et al Italian Sarcoma Group: Sorafenib and
everolimus for patients with unresectable high-grade osteosarcoma
progressing after standard treatment: A non-randomised phase 2
clinical trial. Lancet Oncol. 16:98–107. 2015. View Article : Google Scholar
|
|
6
|
Petrilli AS, de Camargo B, Filho VO,
Bruniera P, Brunetto AL, Jesus-Garcia R, Camargo OP, Pena W,
Péricles P, Davi A, et al Brazilian Osteosarcoma Treatment Group
Studies III and IV: Results of the Brazilian Osteosarcoma Treatment
Group Studies III and IV: Prognostic factors and impact on
survival. J Clin Oncol. 24:1161–1168. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yan M, Ni J, Song D, Ding M and Huang J:
Activation of unfolded protein response protects osteosarcoma cells
from cisplatin-induced apoptosis through NF-κB pathway. Int J Clin
Exp Pathol. 8:10204–10215. 2015.
|
|
8
|
Yang TM, Qi SN, Zhao N, Yang YJ, Yuan HQ,
Zhang B and Jin S: Induction of apoptosis through
caspase-independent or caspase-9-dependent pathway in mouse and
human osteosarcoma cells by a new nitroxyl spin-labeled derivative
of podophyllotoxin. Apoptosis. 18:727–738. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hanikoglu F, Cort A, Ozben H, Hanikoglu A
and Ozben T: Epoxomicin sensitizes resistant osteosarcoma cells to
TRAIL induced apoptosis. Anticancer Agents Med Chem. 15:527–533.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hotta T, Suzuki H, Nagai S, Yamamoto K,
Imakiire A, Takada E, Itoh M and Mizuguchi J: Chemotherapeutic
agents sensitize sarcoma cell lines to tumor necrosis
factor-related apoptosis-inducing ligand-induced caspase-8
activation, apoptosis and loss of mitochondrial membrane potential.
J Orthop Res. 21:949–957. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Locklin RM, Federici E, Espina B, Hulley
PA, Russell RG and Edwards CM: Selective targeting of death
receptor 5 circumvents resistance of MG-63 osteosarcoma cells to
TRAIL-induced apoptosis. Mol Cancer Ther. 6:3219–3228. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sonnemann J, Trommer N, Becker S, Wittig
S, Grauel D, Palani CD and Beck JF: Histone deacetylase
inhibitor-mediated sensitization to TRAIL-induced apoptosis in
childhood malignancies is not associated with upregulation of TRAIL
receptor expression, but with potentiated caspase-8 activation.
Cancer Biol Ther. 13:417–424. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sage EK, Kolluri KK, McNulty K, Lourenco
SS, Kalber TL, Ordidge KL, Davies D, Gary Lee YC, Giangreco A and
Janes SM: Systemic but not topical TRAIL-expressing mesenchymal
stem cells reduce tumour growth in malignant mesothelioma. Thorax.
69:638–647. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lamothe B and Aggarwal BB: Ectopic
expression of Bcl-2 and Bcl-xL inhibits apoptosis induced by
TNF-related apoptosis-inducing ligand (TRAIL) through suppression
of caspases-8, 7, and 3 and BID cleavage in human acute myelogenous
leukemia cell line HL-60. J Interferon Cytokine Res. 22:269–279.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Saggioro FP, Neder L, Stávale JN,
Paixão-Becker AN, Malheiros SM, Soares FA, Pittella JE, Matias CC,
Colli BO, Carlotti CG Jr, et al: Fas, FasL, and cleaved caspases 8
and 3 in glioblastomas: A tissue microarray-based study. Pathol Res
Pract. 210:267–273. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Owa C, Messina ME Jr and Halaby R:
Triptolide induces lysosomal-mediated programmed cell death in
MCF-7 breast cancer cells. Int J Womens Health. 5:557–569.
2013.PubMed/NCBI
|
|
17
|
Pan J: RNA polymerase - an important
molecular target of triptolide in cancer cells. Cancer Lett.
292:149–152. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu Q: Triptolide and its expanding
multiple pharmacological functions. Int Immunopharmacol.
11:377–383. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Alvarez FJ, Kisseberth W, Hosoya K,
Lara-Garcia A, Kosarek C, Murahari S, Au JL, Wientjes MG, Couto J
and Couto G: Postoperative adjuvant combination therapy with
doxorubicin and noncytotoxic suramin in dogs with appendicular
osteosarcoma. J Am Anim Hosp Assoc. 50:12–18. 2014. View Article : Google Scholar
|
|
20
|
Arndt CA, Koshkina NV, Inwards CY, Hawkins
DS, Krailo MD, Villaluna D, Anderson PM, Goorin AM, Blakely ML,
Bernstein M, et al: Inhaled granulocyte-macrophage colony
stimulating factor for first pulmonary recurrence of osteosarcoma:
Effects on disease-free survival and immunomodulation. A report
from the Children's Oncology Group. Clin Cancer Res. 16:4024–4030.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Rakha EA, Tan PH, Shaaban A, Tse GM,
Esteller FC, van Deurzen CH, Purnell D, Stotter A, Chan T,
Yamaguchi R, et al: Do primary mammary osteosarcoma and
chondrosarcoma exist? A review of a large multi-institutional
series of malignant matrix-producing breast tumours. Breast.
22:13–18. 2013. View Article : Google Scholar
|
|
22
|
Reno TA, Kim JY and Raz DJ: Triptolide
inhibits lung cancer cell migration, invasion, and metastasis. Ann
Thorac Surg. 100:1817–1824; discussion 1824–1825. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
van Raam BJ and Salvesen GS: Proliferative
versus apoptotic functions of caspase-8 Hetero or homo: The
caspase-8 dimer controls cell fate. Biochim Biophys Acta.
1824:113–122. 2012. View Article : Google Scholar
|
|
24
|
Saitoh Y, Hamano A, Mochida K, Kakeya A,
Uno M, Tsuruyama E, Ichikawa H, Tokunaga F, Utsunomiya A, Watanabe
T, et al: A20 targets caspase-8 and FADD to protect HTLV-I-infected
cells. Leukemia. Oct 6–2015, (Epub ahead of print) http://dx.doi.org/10.1038/leu.2015.267.
|
|
25
|
Kang S, Fernandes-Alnemri T, Rogers C,
Mayes L, Wang Y, Dillon C, Roback L, Kaiser W, Oberst A, Sagara J,
et al: Caspase-8 scaffolding function and MLKL regulate NLRP3
inflammasome activation downstream of TLR3. Nat Commun. 6:75152015.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Deng XU, Xia KE, Chen PO, Ali Sheikh MS,
Yang DF, Li SM and Yang TL: Reversion of left ventricle remodeling
in spontaneously hypertensive rats by valsartan is associated with
the inhibition of caspase-3, -8 and -9 activities. Biomed Rep.
3:533–536. 2015.PubMed/NCBI
|
|
27
|
Lin ML, Lu YC, Su HL, Lin HT, Lee CC, Kang
SE, Lai TC, Chung JG and Chen SS: Destabilization of CARP mRNAs by
aloe-emodin contributes to caspase-8-mediated p53-independent
apoptosis of human carcinoma cells. J Cell Biochem. 112:1176–1191.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kaseta MK, Gomatos IP, Khaldi L,
Tzagarakis GP, Alevizos L, Themistocleous GS, Leandros E and
Soucacos PN: Prognostic value of bax, cytochrome C, and caspase-8
protein expression in primary osteosarcoma. Hybridoma (Larchmt).
26:355–362. 2007. View Article : Google Scholar
|
|
29
|
Kataoka T: The caspase-8 modulator c-FLIP.
Crit Rev Immunol. 25:31–58. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhao F, Huang W, Ousman T, Zhang B, Han Y,
Clotaire DZ, Wang C, Chang H, Luo H, Ren X, et al: Triptolide
induces growth inhibition and apoptosis of human laryngocarcinoma
cells by enhancing p53 activities and suppressing E6-mediated p53
degradation. PLoS One. 8:e807842013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lee JY, Jung KH, Morgan MJ, Kang YR, Lee
HS, Koo GB, Hong SS, Kwon SW and Kim YS: Sensitization of
TRAIL-induced cell death by 20(S)-ginsenoside Rg3 via CHOP-mediated
DR5 upregulation in human hepatocellular carcinoma cells. Mol
Cancer Ther. 12:274–285. 2013. View Article : Google Scholar
|
|
32
|
Kim EY, Yu JS, Yang M and Kim AK:
Sub-toxic dose of apigenin sensitizes HepG2 cells to TRAIL through
ERK-dependent up-regulation of TRAIL receptor DR5. Mol Cells.
35:32–40. 2013. View Article : Google Scholar
|
|
33
|
Carter BZ, Mak DH, Schober WD, Dietrich
MF, Pinilla C, Vassilev LT, Reed JC and Andreeff M: Triptolide
sensitizes AML cells to TRAIL-induced apoptosis via decrease of
XIAP and p53-mediated increase of DR5. Blood. 111:3742–3750. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gordy C, Liang J, Pua H and He YW: c-FLIP
protects eosinophils from TNF-α-mediated cell death in vivo. PLoS
One. 9:e1077242014. View Article : Google Scholar
|
|
35
|
Haag C, Stadel D, Zhou S, Bachem MG,
Möller P, Debatin KM and Fulda S: Identification of c-FLIP(L) and
c-FLIP(S) as critical regulators of death receptor-induced
apoptosis in pancreatic cancer cells. Gut. 60:225–237. 2011.
View Article : Google Scholar
|
|
36
|
Schleich K, Buchbinder JH, Pietkiewicz S,
Kähne T, Warnken U, Öztürk S, Schnölzer M, Naumann M, Krammer PH
and Lavrik IN: Molecular architecture of the DED chains at the
DISC: regulation of procaspase-8 activation by short DED proteins
c-FLIP and procaspase-8 prodomain. Cell Death Differ. Oct 23–2015,
(Epub ahead of print) http://dx.doi.org/10.1038/cdd.2015.137.
|
|
37
|
Chen Z, Sangwan V, Banerjee S, Chugh R,
Dudeja V, Vickers SM and Saluja AK: Triptolide sensitizes
pancreatic cancer cells to TRAIL-induced activation of the death
receptor pathway. Cancer Lett. 348:156–166. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Jiang X, Chen Y, Fan X, Zhang H and Kun L:
Osteogenesis and mineralization in a rabbit mandibular distraction
osteogenesis model is promoted by the human LMP-1 gene. J Orthop
Res. 33:521–526. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ishioka S, Sagae S, Ito E and Kudo R:
Ultrastructural study of benign, low-malignant potential (LMP), and
malignant ovarian tumors. Med Electron Microsc. 37:37–44. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Pan H, Li X, Wang J, Zhang K, Yang H, Li
Z, Zheng Z and Liu H: LIM mineralization protein-1 enhances bone
morphogenetic protein-2-mediated osteogenesis through activation of
ERK1/2 MAPK pathway and upregulation of Runx2 transactivity. J Bone
Miner Res. 30:1523–1535. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Aisa MC, Rahman S, Senin U, Maggio D and
Russell RG: Cathepsin B activity in normal human osteoblast-like
cells and human osteoblastic osteosarcoma cells (MG-63): Regulation
by interleukin-1 beta and parathyroid hormone. Biochim Biophys
Acta. 1290:29–36. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Jiao WJ, Xu J, Pan H, Wang TY and Shen Y:
Effect of endothelin-1 in esophageal squamous cell carcinoma
invasion and its correlation with cathepsin B. World J
Gastroenterol. 13:4002–4005. 2007. View Article : Google Scholar : PubMed/NCBI
|
